GLP-1 receptor agonists, originally derived from Gila monster venom, now show evidence of protecting not just the heart but also the kidneys, liver, lungs, and brain across multiple disease states.
5 organ systems with evidence of GLP-1RA protectionHeart, kidney, liver, lung, and brain all show evidence of benefit from GLP-1 receptor agonism beyond metabolic effects
What the researchers found
GLP-1RAs have established benefits in type 2 diabetes, body weight management, and cardiovascular risk protection. Beyond these, growing evidence supports organ-protective effects in multiple systems:
- Renal: GLP-1RAs show kidney-protective effects that may slow chronic kidney disease progression
- Hepatic: Benefits in non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease
- Respiratory: Emerging evidence for lung-protective effects
- Neurological: Potential neuroprotective benefits in neurodegenerative diseases
The review explores both weight-dependent and weight-independent mechanisms underlying these multi-organ benefits, suggesting that GLP-1 receptor signaling has direct protective effects on tissues throughout the body.
Why it matters
The discovery that a peptide from Gila monster venom could protect multiple organ systems represents one of the most remarkable translational stories in medicine. If GLP-1RAs can truly protect the heart, kidneys, liver, lungs, and brain, they could become the most widely prescribed drug class of the 21st century. Understanding which organ-protective effects are direct (via GLP-1 receptor signaling) versus indirect (via weight loss) is crucial for optimizing treatment and identifying which patients will benefit most.
How the study worked
Narrative review published in Trends in Endocrinology & Metabolism examining the latest clinical and preclinical evidence for GLP-1RA-mediated organ protection. The authors synthesize evidence across cardiovascular, renal, hepatic, respiratory, and neurological disease areas, discussing both clinical trial results and mechanistic data.
What this study cannot tell us
The review notes that while cardiovascular benefits are supported by large outcome trials, evidence for renal, hepatic, respiratory, and neurological protection is at varying stages of maturity. Some organ-protective effects may be primarily mediated by weight loss rather than direct GLP-1 receptor effects. Publication bias may favor positive results in newer application areas. The review doesn't provide a systematic quality assessment of the evidence across disease areas.
How to read the evidence
This is a narrative review in a high-impact endocrinology journal. The evidence strength varies by organ system: cardiovascular protection is supported by multiple large randomized outcome trials (high evidence), while respiratory and neurological benefits have less mature evidence bases. The review synthesizes rather than systematically grades the evidence.
When this study was published
Published in 2025 in Trends in Endocrinology & Metabolism, this is a very current review reflecting the latest evidence for GLP-1RA organ protection. The field is evolving rapidly, with new trial data emerging regularly.
The bigger picture
GLP-1RAs are undergoing a remarkable expansion from diabetes drugs to multi-organ protective agents. This mirrors a broader trend in medicine of recognizing that metabolic health is intertwined with the health of virtually every organ system. The story of exendin-4 — from lizard venom to one of the most important drug classes in modern medicine — also illustrates the unpredictable power of natural product drug discovery in the peptide space.
Questions still open
- Which organ-protective effects of GLP-1RAs are direct receptor-mediated versus secondary to weight loss and metabolic improvement?
- Will GLP-1RAs receive regulatory approval for organ-protective indications beyond diabetes, obesity, and cardiovascular risk?
- Could engineered GLP-1RA variants be developed with enhanced tissue-specific organ protection?
Common questions
How did Gila monster venom lead to GLP-1 drugs?
Beyond diabetes and weight loss, what other organs do GLP-1 drugs protect?
Read the original research
Glucagon-like peptide-1 receptor agonism and end-organ protection.
Trends in endocrinology and metabolism: TEM, 36(4), 301-315
Citation
Daniels, Samuel; Karlsson, Cecilia; Schrauwen, Patrick; Parker, Victoria E R. (2025). Glucagon-like peptide-1 receptor agonism and end-organ protection.. Trends in endocrinology and metabolism: TEM, 36(4), 301-315. https://doi.org/10.1016/j.tem.2025.01.002